HIF pathway mutations and erythrocytosis

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


Erythrocytosis is present when there is an increase in the red cell mass, usually accompanied by an elevated hemoglobin and hematocrit. This occurs when there is an intrinsic defect in the erythroid component of the bone marrow or for secondary reasons when an increase in erythropoietin production drives red cell production. In normoxic conditions, HIF-alpha interacts with the other proteins in the HIF pathway and is destroyed, but in hypoxic conditions, HIF-alpha binds to HIF-beta. and alters the expression of downstream genes, including the erythropoietin gene. The end result is an increase in erythropoietin production. Mutations in any of the genes in the HIF pathway could lead to changed proteins, abnormalities in the degradation of HIF-alpha and, ultimately, result in increased erythropoietin levels. A number of mutations in the VHL, PHD2, and HIF2A genes have been identified in individuals. These mutations lead to erythrocytosis. The clinical results of these mutations may include some major thromboembolic events in young patients.
Original languageEnglish
Pages (from-to)93-101
Number of pages9
Issue number1
Publication statusPublished - 2010

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'HIF pathway mutations and erythrocytosis'. Together they form a unique fingerprint.

Cite this